NCT05436223View on ClinicalTrials.gov

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

August 9, 2024

Study Completion Date

August 9, 2026

Conditions
B-cell Non-Hodgkin's Lymphoma
Interventions
DRUG

Human CD19Targeted T Cells Injection

A single dose of predetermined level CAR-positive T cells will be infused.

Trial Locations (1)

200032

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai

Sponsors
All Listed Sponsors
collaborator

Shanghai Zhongshan Hospital

OTHER

lead

Hrain Biotechnology Co., Ltd.

INDUSTRY